Vericel Announces Publication Of Results From Phase 3 Debride And Protect Study Of Thermal Burn Patients Treated With NexoBrid
Portfolio Pulse from Benzinga Newsdesk
Vericel Corporation has announced the publication of results from the Phase 3 DETECT study assessing the safety and efficacy of NexoBrid in the Journal of Burn Care & Research. The study showed that treatment with NexoBrid resulted in early complete eschar removal in more than 90% of treated patients, reduced surgery, and was safe and well-tolerated without deleterious effects on wound closure and scarring. These results served as the foundation for the FDA approval of NexoBrid for commercial use in the U.S.
September 28, 2023 | 12:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The positive results from the Phase 3 DETECT study and subsequent FDA approval for commercial use of NexoBrid could potentially boost Vericel's market position and stock value.
The successful Phase 3 study and FDA approval for NexoBrid indicate a positive outlook for Vericel. This could lead to increased investor confidence and a potential rise in stock value in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100